Arpeggio makes medicine to alter gene expression and fight drug resistance in cancer. We do this by combining CRISPR-engineer cell models, high throughput transcriptomics, and machine learning to discover novel chemistry against challenging targets. Arpeggio has partnered with top-tier Pharma companies like Pfizer & Janssen, and its pipeline contains a combination of first and best-in-class assets positioned against rare cancer types with high unmet need.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Colorado
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Oncology
Lead Product in Development:
Small Molecule Therapies in Triple Negative Breast Cancer and High Grade Serous Ovarian Cancer
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
